Özet:

Stage II and stage III (T1-4/N1-2/M0) colon cancers are known as locally advanced colon cancer (LACC). About 15% of colon cancers present as LACC without signs of metastasis. Standard treatment of LACC is based on complete oncologic resection followed by adjuvant chemotherapy (AC). In the surgical treatment of LACC, multivisceral resections are applied to obtain R0 resection. Despite such aggressive resections, the rate of obtaining R0 in LACC varies between 40% and 90%, and 5-year survival is between 28% and 73%. Neoadjuvant chemotherapy (NAC) is widely used in the treatment of gastrointestinal system malignancies, such as locally advanced gastric, esophageal and rectal cancers and locally advanced breast cancer. In the literature, there has been an increase in studies on the use of NAC in LACC. These show that NAC appears to be safe and provides similar overall survival compared to adjuvant CT in LACC, that the R0 resection rate is increased in patients who have undergone NAC, that there is no significant increase in postoperative complications or mortality, and that there is also significant downstaging of tumor and lymph node stages in patients who have undergone NAC.

Anahtar Kelimeler: